Gaurav Aggarwal - 18 Feb 2025 Form 4 Insider Report for Unicycive Therapeutics, Inc. (UNCY)

Role
Director
Signature
/s/ Gaurav Aggarwal
Issuer symbol
UNCY
Transactions as of
18 Feb 2025
Net transactions value
-$686,000
Form type
4
Filing time
19 Feb 2025, 11:55:27 UTC
Previous filing
10 Oct 2024
Next filing
22 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UNCY Common Stock Conversion of derivative security +1,400,000 +14% 11,370,152 18 Feb 2025 By Vivo Opportunity Fund Holdings L.P. F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UNCY Series A-2 Prime Preferred Stock Disposed to Issuer $686,000 -686 -18% $1000.00 3,119 18 Feb 2025 Common Stock 1,400,000 $0.4900 By Vivo Opportunity Fund Holdings L.P. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $0.49, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.
F2 Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3 The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.